Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
López-Macías C, Torres M, Armenta-Copca B, Wacher NH, Castro-Castrezana L, Colli-Domínguez AA, Rivera-Hernández T, Torres-Flores A, Damián-Hernández M, Ramírez-Martínez L, la Rosa GP, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Carranza C, Juárez E, Zamudio-Meza H, Carreto-Binaghi LE, Viettri M, Romero-Rodríguez D, Palencia A, Reyna-Rosas E, Márquez-García JE, Sarfati-Mizrahi D, Sun W, Chagoya-Cortés HE, Castro-Peralta F, Palese P, Krammer F, García-Sastre A, Lozano-Dubernard B.
López-Macías C, et al. Among authors: torres m.
Vaccine. 2024 Nov 10;43(Pt 2):126511. doi: 10.1016/j.vaccine.2024.126511. Online ahead of print.
Vaccine. 2024.
PMID: 39527880